DL-40
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The DL-40 cell line is a human lymphoma cell line, emerged from a 64-year-old woman’s peripheral blood characterized by aggressive large cell lymphoma that underwent leukemic conversion. These cells grew in suspension, either as single entities or in clusters, featuring abundant cytoplasm encompassing large, round, or multiple nuclei that exhibited a positive reaction to acid phosphatase. Displaying a Ki-1 antigen (CD30), E+, CD2+, CD4+, CD45+, Ia+ phenotype, the cells carried rearranged T-cell receptor beta chains while lacking CD15, HTLV-I, and Epstein-Barr virus nuclear antigen. Examination of the cell line’s chromosomes revealed a karyotype characteristic of human females, featuring intricate hyperdiploid irregularities. Notably, DL-40 cells, when implanted into immune-compromised hamsters or nude mice, generated tumors mirroring the original lymphoma histology.
Why choose DL-40 from AcceGen?
DL-40 boasts excellent quality and viability, backed by meticulous quality control. It arrives sterile and is devoid of mycoplasma, fungi, bacteria, and human pathogens, ensuring reliability for a range of research applications.
| Product Code | DL40 |
| Species | Human |
| Cat.No | ABC-TC0210 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoid |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Anaplastic Large Cell Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
With its unique attributes, the DL-40 cell line assumes a pivotal role in unraveling the intricacies of Ki-1-positive non-Hodgkin’s lymphoma biology. Serving as a robust in vitro model, it facilitates the exploration of key determinants influencing tumor survival within the context of anaplastic large-cell lymphoma. Moreover, its utility extends to investigating the mechanisms underlying lymph node metastasis and propels advancements in therapeutic modalities, ultimately contributing to the targeted development of innovative drugs.
